Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


GREY:BIOAF - Post by User

Comment by Boomskidon Jan 15, 2023 9:13am
112 Views
Post# 35224114

RE:RE:RE:Typos

RE:RE:RE:TyposThe point, poof, is how Bioasis got itself into this situation and whether management has acted in the best interests of the shareholders. I'd like to see an investigation. A legal action against me would get it all on the table. A submission to the court after the AGM may get some questions into the system. The option of a large submission to regulators and the TSXV is available. I have that mostly written out,obviously. 

Could regulators halt all actions by and against Bioasis while Bioasis is investigated? Do shareholders have a meaningful vote or have shareholders been checkmated? If so, were any of the actions or inactions of the company purposely designed to cause the checkmate? Could the checkmate have been avoided? 

About getting out of the current situation, a single deal would clean up the finances. My question remains, has Bioasis postponed, delayed, discouraged or otherwise prevented deals from getting done in favour getting this sellout done? 

The Ellipses leak and all of Rathjen's activities ought to be examined including whether she disclosed enough to the BoD to allow them to make good judgements about this sellout and other things.

And, poof, have you figured out the Ellipses business model or do I need to explain it to you?

jd

<< Previous
Bullboard Posts
Next >>